Elliott P J, Mackic J B, Graney W F, Bartus R T, Zlokovic B V
Alkermes Inc., Los Angeles, California, USA.
Invest Ophthalmol Vis Sci. 1995 Nov;36(12):2542-7.
To determine if the bradykinin agonist, RMP-7, could increase the ocular tissue concentration of agents that normally have limited access across the blood-ocular barriers. The extracellular space marker, sucrose, and the anti-viral drug, ganciclovir, were tested.
Using the perfused eye method in guinea pigs, RMP-7 (1 microgram/kg over 5 minutes) or saline were administered intraarterially into the ocular circulation before either radiolabeled sucrose or ganciclovir (0.4 to 0.6 microCi/ml per minute). At time intervals ranging from 0.25 minute to 10 minutes, perfused eyes were removed, and the radioactivity within various compartments was measured using liquid scintillography.
Pretreatment with RMP-7 significantly increased uptake of both sucrose (up to 4.5-fold) and ganciclovir (up to 2-fold) into the guinea pig retina and lens. Smaller and less consistent effects were observed in other eye compartments.
This report demonstrates that RMP-7 enhances the permeability of blood-ocular barriers, and it provides the first pharmacologic evidence for a means to enhance the concentration of ganciclovir into the retina. Thus, these data support the concept that RMP-7 may prove to be a useful adjunct for enhanced delivery of therapeutics to the eye under conditions in which ocular barriers limit treatment.
